[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343044-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343044-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","geriatric-breast-cancer-molecular-surrogates-and-treatment-a-review-meta-analysis","Geriatric Breast Cancer - Molecular Surrogates and Treatment: A Review - Meta-analysis","","Breast cancer treatment for patients is mainly guided by age, disease stage, and tumor molecular subtype. This review and meta-analysis updates staging approaches, molecular surrogate concepts, and treatment choices for women over 70 using systematic evidence from 2013-2023. PRISMA and PICO were followed with searches across Web of Science, PubMed, MEDLINE, and Scopus, quality assessed by MMAT. Meta-analysis used RevMan 5.4 with random effects at 0.05 significance, yielding 17 included studies with 39,906 patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/geriatric-breast-cancer-molecular-surrogates-and-treatment-a-review-meta-analysis/343044/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/geriatric-breast-cancer-molecular-surrogates-and-treatment-a-review-meta-analysis/343044.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What patient factors primarily guide breast cancer treatment decisions in this review?","Question",{"text":63,"@type":64},"Treatment recommendations are primarily driven by patient age, disease staging, and the tumor molecular subtype.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were studies identified and assessed in the systematic review?",{"text":68,"@type":64},"The review followed PRISMA with a PICO framework, searched Web of Science, PubMed, MEDLINE, and Scopus, and used the Mixed Methods Appraisal Tool to assess study quality.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the overall meta-analysis results in terms of studies and patients included?",{"text":72,"@type":64},"A total of 4,151 research articles were screened, and 17 articles with 39,906 patients were included in the review and meta-analysis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343044,1790115186,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Volume 15, Number 4; 1602-1618, August 2024  \n[http://dx.doi.org/10.14336/AD.2023.1002](http://dx.doi.org/10.14336/AD.2023.1002)  \nReview  \nGeriatric Breast Cancer: Staging, Molecular Surrogates, and Treatment. A Review & Meta-analysis  \nVasco C. Fonseca1*, Zacharoula Sidiropoulou2  \n1Department of Oncology, Hospital Centre of West Lisbon, Portugal. 2General Surgery Department, Breast Unit, Hospital Centre of West Lisbon, Portugal  \n[Received July 21, 2023; Revised September 29, 2023; Accepted October 2, 2023]  \nABSTRACT: Breast cancer (BC) is one of the most frequent cancers in females across the globe. Treatment recommendations for BC patients are primarily driven by patient age, staging and tumor molecular subtype. Thus, we updated the general overview of BC staging, molecular surrogates, and treatment choices for women >70 years based on a systematic study encompassing the years 2013-2023. A PRISMA guidelines and PICO framework were followed, and relevant research articles were searched using different data bases (Web of Sciences, PubMed, MEDLINE, and Scopus). Mixed Methods Appraisal Tool was used for studies quality assessment. The research articles that made it into the systematic review were compiled using qualitative criteria. In the meanwhile, heterogeneity was determined using meta-analysis with RevMan 5.4. We applied a random effects model with a 0.05 significance level. Overall, there were 4151 research articles, after screening only 17 articles with 39,906 patients were included. Conclusion: Elderly patients with breast cancer should be treated differently in an adapted way. The treatment should not be the same worldwide due to different health systems. Molecular surrogates are different in geriatric patients. Surgery is the best option for treatment in this subset of patients. We need to have therapeutic decision appointments for elderly patients with breast cancer. The guidelines and medical authority should be used in the best decision.  \nKey words: Breast Cancer, elderly, molecular subtypes, Cancer staging.  \nIntroduction  \nWithin the realm of breast cancer research, a significant gap persists in the comprehensive understanding of disease progression, treatment outcomes, and molecular intricacies in geriatric patients aged 70 and above. While substantial progress has been made in breast cancer diagnosis and treatment, a notable disparity exists in the representation of older women within clinical trials and research endeavors. This study seeks to bridge this gap by shedding light on the unique characteristics of breast cancer in the geriatric population, particularly focusing on staging, molecular profiles, and treatment responses [1] . The importance of addressing this gap is underscored by the growing aging demographic worldwide, where a considerable proportion of breast cancer cases occur in women above 70. Current treatment strategies often stem  \nfrom studies involving younger patients, potentially leading to suboptimal therapeutic decisions for older individuals.  \nBy elucidating the molecular underpinnings specific to geriatric patients, this study strives to provide valuable insights that can lead to tailored and more effective treatment approaches for this understudied population. Ultimately, the findings from this systematic review and meta-analysis aim to inform clinical practice, enhance treatment outcomes, and improve the quality of life for older women battling breast cancer.\"  \nMolecular surrogates refer to specific molecular markers, indicators, or characteristics that are used to indirectly measure or predict certain biological processes, disease states, or treatment responses. In the realm of breast cancer, molecular surrogates often encompass various genetic, genomic, and protein-level factors that  \n\n| provide insights into the underlying molecular mechanisms of the disease. These surrogates are particularly valuable in informing treatment decisions, as they can offer a more nuanced underst","cbCaifnrx6bNrAlf","https://ap.wps.com/l/cbCaifnrx6bNrAlf","pdf",1171527,17,"English","# Abstract\n# Introduction\n## Background and research gap in women aged 70+\n## Rationale for molecularly informed treatment\n# Molecular surrogates in breast cancer\n## Definition and role in tumor biology and outcomes\n## Added relevance in geriatric patients\n# Study aims and clinical implications","[{\"question\":\"What patient factors primarily guide breast cancer treatment decisions in this review?\",\"answer\":\"Treatment recommendations are primarily driven by patient age, disease staging, and the tumor molecular subtype.\"},{\"question\":\"How were studies identified and assessed in the systematic review?\",\"answer\":\"The review followed PRISMA with a PICO framework, searched Web of Science, PubMed, MEDLINE, and Scopus, and used the Mixed Methods Appraisal Tool to assess study quality.\"},{\"question\":\"What were the overall meta-analysis results in terms of studies and patients included?\",\"answer\":\"A total of 4,151 research articles were screened, and 17 articles with 39,906 patients were included in the review and meta-analysis.\"}]","Geriatric Breast Cancer - Molecular Surrogates and Treatment: A Review - Meta-analysis | PDF",1790049577,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3dc3fbb83d74feaf3fa302d2ef922e4a.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8fadd8622a4f2b2aecf92220be4191fc.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ff30c4f2c057e4b0720a19d0522af19.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4133fa934dc40446db3c26f608b8639.webp",980,1268]